Company Analysis Standard BioTools Inc.
1. Summary
Advantages
- The stock's return over the last year (42.99%) is higher than the sector average (-2.15%).
- Current debt level 5.39% is below 100% and has decreased over 5 years from 29.37%.
Disadvantages
- Price (1.53 $) is higher than fair price (1.44 $)
- Dividends (0%) are below the sector average (0.53%).
- The company's current efficiency (ROE=-43.75%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Standard BioTools Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5% | -14.6% | -0% |
| 90 days | 10.9% | -6.9% | -0.9% |
| 1 year | 43% | -2.2% | 19.8% |
LAB vs Sector: Standard BioTools Inc. has outperformed the "Healthcare" sector by 45.14% over the past year.
LAB vs Market: Standard BioTools Inc. has outperformed the market by 23.21% over the past year.
Stable price: LAB is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LAB with weekly volatility of 0.83% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (1.53 $) is higher than the fair price (1.44 $).
Price is higher than fair: The current price (1.53 $) is 5.9% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-3.33) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-3.33) is higher than that of the market as a whole (-101.03).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.33) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (1.33) is lower than that of the market as a whole (72.01).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (3.58) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (3.58) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.16) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.16) is higher than that of the market as a whole (-78.03).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 26.89% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (26.89%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-43.75%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-43.75%) is lower than that of the market as a whole (-6.21%).
6.6. ROA
ROA vs Sector: The company's ROA (-29.69%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-29.69%) is lower than that of the market as a whole (38.61%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.79%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
